ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors*
暂无分享,去创建一个
H. Wiley | L. Opresko | H S Wiley | L K Opresko | R Worthylake | R. Worthylake | Rebecca Worthylake | Lee K. Opresko
[1] D A Lauffenburger,et al. Postendocytic trafficking of epidermal growth factor-receptor complexes is mediated through saturable and specific endosomal interactions. , 1994, The Journal of biological chemistry.
[2] G. Plowman,et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[3] H. Wiley,et al. Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system , 1988, The Journal of cell biology.
[4] Y. Yarden,et al. Roles for a Cytoplasmic Tyrosine and Tyrosine Kinase Activity in the Interactions of Neu Receptors with Coated Pits (*) , 1995, The Journal of Biological Chemistry.
[5] E. Harlow,et al. Antibodies: A Laboratory Manual , 1988 .
[6] Y. Yarden,et al. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.
[7] S. Ethier,et al. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[8] J. Welsh,et al. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. , 1990, Science.
[9] L. Cantley,et al. A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling , 1994, Cell.
[10] S. Bonhoeffer,et al. HIV-1 Evolution and Disease Progression , 1996, Science.
[11] Joseph Schlessinger,et al. Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.
[12] W. Dougall,et al. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[13] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[14] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[15] G. Carpenter,et al. The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. , 1993, Oncogene.
[16] R. Bast,et al. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. , 1991, Cancer research.
[17] I. Friedberg,et al. Secondary Dimerization between Members of the Epidermal Growth Factor Receptor Family* , 1997, The Journal of Biological Chemistry.
[18] H. Wiley,et al. Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization. , 1990, The Journal of biological chemistry.
[19] D. Stern,et al. EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. , 1988, The EMBO journal.
[20] G. Carpenter,et al. All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.
[21] A. Lenferink,et al. Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.
[22] C. Waters,et al. Endocytosis of growth factor receptors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.
[23] M. Sliwkowski,et al. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[24] M. Weber,et al. An Incomplete Program of Cellular Tyrosine Phosphorylations Induced by Kinase-defective Epidermal Growth Factor Receptors (*) , 1995, The Journal of Biological Chemistry.
[25] H. Steven Wiley,et al. A steady state model for analyzing the cellular binding, internalization and degradation of polypeptide ligands , 1981, Cell.
[26] M. Chabre. Regulation of cellular signal transduction pathways by desensitization and amplification , 1994 .
[27] J. Schlessinger,et al. Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB‐2 protein in the mammary tumor cell line SK‐BR‐3. , 1988, The EMBO journal.
[28] Y. Yarden,et al. Neu and its ligands: From an oncogene to neural factors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.
[29] J. Olefsky,et al. Involvement of ErbB2 in the Signaling Pathway Leading to Cell Cycle Progression from a Truncated Epidermal Growth Factor Receptor Lacking the C-terminal Autophosphorylation Sites (*) , 1996, The Journal of Biological Chemistry.
[30] D. Goeddel,et al. Identification of Heregulin, a Specific Activator of p185erbB2 , 1992, Science.
[31] D A Lauffenburger,et al. The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. , 1991, The Journal of biological chemistry.
[32] D. Agard,et al. Fluorescence microscopy in three dimensions. , 1989, Methods in cell biology.
[33] W. Dougall,et al. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Massagué,et al. Membrane-anchored growth factors. , 1993, Annual review of biochemistry.
[35] J. Bartek,et al. Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Taylor‐Papadimitriou,et al. Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells. , 1993, Oncogene.
[37] H. Wiley,et al. Altered degradation of epidermal growth factor in a diphtheria toxin‐resistant clone of KB cells , 1985, Journal of cellular physiology.
[38] D. Lauffenburger,et al. Regulation of postendocytic trafficking of the epidermal growth factor receptor through endosomal retention. , 1994, The Journal of biological chemistry.
[39] P. Jolicoeur,et al. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.
[40] H. Wiley,et al. Global modulation of the epidermal growth factor receptor is triggered by occupancy of only a few receptors. Evidence for a binary regulatory system in normal human fibroblasts. , 1989, The Journal of biological chemistry.
[41] H. Wiley,et al. Structural Aspects of the Epidermal Growth Factor Receptor Required for Transmodulation of erbB-2/neu* , 1997, The Journal of Biological Chemistry.
[42] Y. Yarden,et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.
[43] R. Cardiff,et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[44] Dihua Yu,et al. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. , 1997, Cancer research.
[45] E. Kornilova,et al. Surface expression of erbB-2 protein is post-transcriptionally regulated in mammary epithelial cells by epidermal growth factor and by the culture density. , 1992, Oncogene.
[46] K. Carraway. Involvement of the neuregulins and their receptors in cardiac and neural development. , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.
[47] K. Carraway,et al. Inhibition of epidermal growth factor receptor aggregation by an antibody directed against the epidermal growth factor receptor extracellular domain. , 1993, The Journal of biological chemistry.
[48] M. Kraus,et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.
[49] J. Mendelsohn,et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. , 1984, The Journal of biological chemistry.
[50] H. Wiley,et al. Endocytosis and Lysosomal Targeting of Epidermal Growth Factor Receptors Are Mediated by Distinct Sequences Independent of the Tyrosine Kinase Domain (*) , 1995, The Journal of Biological Chemistry.
[51] L. Frati,et al. Surface distribution and internalization of erbB-2 proteins. , 1992, Experimental cell research.
[52] Walter Gilbert,et al. Ligands for ErbB-family receptors encoded by a neuregulin-like gene , 1997, Nature.
[53] Y. Yarden,et al. ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.
[54] H. Wiley,et al. Intracellular processing of epidermal growth factor and its effect on ligand-receptor interactions. , 1985, The Journal of biological chemistry.